Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 2
2021 5
2022 7
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome.
Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, Palacios-Berraquero ML, Martin-Mallo A, Calviño C, Español-Rego M, Ceballos C, Lozano T, San Martin-Uriz P, Vilas-Zornoza A, Rodriguez-Diaz S, Martinez-Turrillas R, Jauregui P, Alignani D, Viguria MC, Redondo M, Pascal M, Martin-Antonio B, Juan M, Urbano-Ispizua A, Rodriguez-Otero P, Alfonso-Pierola A, Paiva B, Lasarte JJ, Inoges S, Lopez-Diaz de Cerio A, San-Miguel J, Fernandez de Larrea C, Hernaez M, Rodriguez-Madoz JR, Prosper F. Rodriguez-Marquez P, et al. Among authors: oliver caldes a. Sci Adv. 2022 Sep 30;8(39):eabo0514. doi: 10.1126/sciadv.abo0514. Epub 2022 Sep 30. Sci Adv. 2022. PMID: 36179026 Free PMC article.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060
Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma.
Oliver-Caldes A, Soler-Perromat JC, Lozano E, Moreno D, Bataller A, Mozas P, Garrote M, Setoain X, Aróstegui JI, Yagüe J, Tovar N, Jiménez R, Rodríguez-Lobato LG, Cibeira MT, Rosiñol L, Bladé J, Juan M, Fernández de Larrea C. Oliver-Caldes A, et al. Front Oncol. 2022 Jul 5;12:936993. doi: 10.3389/fonc.2022.936993. eCollection 2022. Front Oncol. 2022. PMID: 35865461 Free PMC article.
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Oliver-Caldes A, Jiménez R, Español-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, González-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodríguez-Lobato LG, Campistol JM, Calvo G, Bladé J, Rosiñol L, Juan M, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldes A, et al. J Immunother Cancer. 2021 Dec;9(12):e003783. doi: 10.1136/jitc-2021-003783. J Immunother Cancer. 2021. PMID: 34876408 Free PMC article.
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beyá M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guiñon A, Salamero O, Sampol A, Merchan BM, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldés A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedéu JF, Colomer D, Brunet S, Sierra J, Esteve J. Bataller A, et al. Among authors: oliver caldes a. Blood Adv. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. Blood Adv. 2022. PMID: 34911079 Free PMC article.
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.
Moreno DF, Pereira A, Tovar N, Cibeira MT, Magnano L, Rozman M, López-Guerra M, Colomer D, Martín-Antonio B, Jiménez-Segura R, Isola I, Rodríguez-Lobato LG, Oliver-Caldés A, Mena MP, Rosiñol L, Bladé J, Fernández de Larrea C. Moreno DF, et al. Among authors: oliver caldes a. Cancers (Basel). 2021 Apr 23;13(9):2055. doi: 10.3390/cancers13092055. Cancers (Basel). 2021. PMID: 33922804 Free PMC article.
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno DF, López-Guerra M, Paz S, Oliver-Caldés A, Mena MP, Correa JG, Battram AM, Osuna M, Rivas-Delgado A, Rodríguez-Lobato LG, Cardús O, Tovar N, Cibeira MT, Jiménez-Segura R, Bladé J, Rosiñol L, Colomer D, Fernández de Larrea C. Moreno DF, et al. Among authors: oliver caldes a. Br J Haematol. 2023 Jan;200(2):187-196. doi: 10.1111/bjh.18502. Epub 2022 Oct 9. Br J Haematol. 2023. PMID: 36210485 Free PMC article.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Bataller A, et al. Among authors: oliver caldes a. Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32510599 Free article. Clinical Trial.
19 results